According to the ETF Finder at ETF Channel, SRPT makes up 2.59% of the SPDR S&P Biotech ETF (XBI) which is lower by about 0.7% on the day Friday.
In afternoon trading Friday, SRPT was down about 0.2% on the day.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Following speculation that Sarepta Therapeutics's (SRPT) muscular dystrophy therapy is struggling to gain approval, Janney highlighted downside risk to the stock.
Sarepta (SRPT) stock is advancing in afternoon trading after a government website indicated the biopharmaceutical company is recruiting patients in its Phase III trials to treat Duchenne muscular dystrophy.